- This licensed small molecule program is designed to tackle crucial unmet medical needs within the realm of autoimmune diseases.
- The program expands Boehringer Ingelheim’s existing pipeline, underscoring its dedication to providing innovative treatments for individuals living with inflammatory conditions.
Ingelheim, Germany, and Tokyo, Japan, [October 30, 2025] – Boehringer Ingelheim and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and COO: Abdul Mullick) jointly revealed today that Boehringer Ingelheim has secured a license for a pre-clinical program from Kyowa Kirin. This initiative aims to develop a novel, potential first-in-class small molecule compound intended for addressing autoimmune diseases.
Autoimmune conditions pose a significant and expanding worldwide health challenge, impacting about one in ten individuals and placing considerable strain on both patients and medical infrastructures. Even with advancements in therapeutic innovation, a substantial demand persists for more potent and enduring treatment alternatives. Boehringer Ingelheim, a renowned leader in the research and development of autoimmune diseases, is pioneering fresh methodologies that target the underlying origins of these conditions, striving to deliver highly specific new treatments.
“Our dedication to providing transformative therapies for individuals suffering from autoimmune diseases remains steadfast. We are delighted to incorporate a program with potential first-in-class status into our expanding portfolio,” stated Carine Boustany, US Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim. “This collaboration marks a crucial stride towards introducing groundbreaking treatments for patients.”
Takeyoshi Yamashita, Ph.D., Executive Vice President and Chief Medical Officer of Kyowa Kirin, remarked, “This compound, identified thanks to Kyowa Kirin’s profound proficiency in innovative technology and disease biology, shows immense promise. By harnessing Boehringer Ingelheim’s acclaimed expertise in inflammatory diseases, we are optimistic that this novel solution will be efficiently advanced and made available to the patients who stand to benefit the most.”
Per the terms of this agreement, Boehringer Ingelheim will acquire exclusive global rights from Kyowa Kirin to further develop this small molecule program. Kyowa Kirin stands to gain up to €640 million, encompassing an initial upfront payment, along with milestone payments tied to development, regulatory, and commercial achievements, plus royalties from any potential future sales.
Boehringer Ingelheim
Boehringer Ingelheim operates as a biopharmaceutical firm engaged in both human and animal healthcare. Recognized as a leading investor in research and development within its sector, the company prioritizes the creation of inventive therapies designed to enhance and prolong lives in therapeutic areas with significant unmet needs. Having maintained its independence since its establishment in 1885, Boehringer Ingelheim adopts a long-range outlook, integrating sustainability across its entire value chain. Our team of approximately 54,500 employees caters to more than 130 markets, contributing to a healthier and more sustainable future. Discover more at .
Kyowa Kirin
Kyowa Kirin is committed to identifying and providing innovative medicines and therapies that offer transformative value. As a global specialty pharmaceutical company based in Japan, Kyowa Kirin has dedicated over 70 years to drug discovery and biotechnological advancement. The company is presently engaged in developing advanced antibodies, cell, and gene therapies with the capacity to assist patients facing critical unmet medical needs, including conditions related to bone & mineral, difficult-to-treat hematological/hemato-oncological ailments, and rare diseases. A collective dedication to Kyowa Kirin’s principles, to enduring growth, and to bringing joy to people, binds the company worldwide. Further information about Kyowa Kirin’s operations is available at .
Important Notice for Readers
Originating from our Corporate Headquarters in Ingelheim, Germany, this press release is designed to offer insights into our worldwide operations. Kindly note that details concerning the approval status and labeling of authorized products can differ by country, and a specific press release pertaining to this subject might have been released in the nations where we conduct business.
For Media Inquiries
Contact Boehringer Ingelheim:
Dr. Reinhard Malin
Boehringer Ingelheim Corporate Center GmbH
Innovation Unit/Bio Comms, Corp. Affairs
Media + PR
Contact Kyowa Kirin:
Nobuyuki Manita
Kyowa Kirin Co., Ltd. Corporate Communications
Media: media@kyowakirin.com
Investors: ir@kyowakirin.com
Attachment
